Peralta-Reich says that they will not experience the full benefits of the medication
It activates receptors in the pancreas for blood sugar management by regulating insulin and inhibiting glucagon release
That same year, injectable semaglutide in SUSTAIN-6 achieved a more substantial 26% MACE reduction (HR 0.74, 95% CI 0.580.95, p = 0.02), driven largely by a 39% lower stroke incidence (HR 0.61, 95% CI 0.380.99), though CV death showed no significant change (HR 0.98, 95% CI 0.651.48), with notable stroke benefits in relevant subgroups [45]
A 1 mL insulin syringe with 100-unit markings provides the precision needed for accurate starting doses
Participants taking the drug, called orforglipron, lost an average of 9.4% to 14.7% of their body weight, depending on the dose given, after 36 weeks, according to the phase 2 clinical trial results, which were published in the New England Journal of Medicine